Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation
Related Experiment Video
Updated: Aug 20, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Sebastian Scholl1, Ivan F Loncarevic, Claudia Krause
1Department of Internal Medicine II (Oncology and Hematology), Friedrich Schiller University, Erlanger Allee 101, 07740 Jena, Germany. sebastian.scholl@med.uni-jena.de
Purpose:
Activating Flt3 mutations are observed in about 30% of patients with acute myeloid leukaemia (AML) and individual Flt3 mutations are applicable for minimal residual disease (MRD) analyses.
Methods:
We investigated the MRD status in four AML patients carrying different Flt3 mutations (three patients with Flt3 length mutations of the juxtamembrane domain, one patient carrying a mutation of the Flt3 tyrosine kinase domain, i.e. Flt3-TKD mutation) who underwent allogeneic peripheral blood stem cell transplantation (PBSCT). Residual leukaemia cells were retrospectively determined by real-time PCR at different time points.
Results:
We can demonstrate a good correlation between the course of MRD status and clinical events in all four investigated patients.
Conclusion:
These examples demonstrate the potential impact of Flt3 based MRD status not only after but also prior to allogeneic PBSCT.
Insights
Minimal residual disease (MRD) analysis targeting Flt3 mutations in acute myeloid leukaemia (AML) shows a strong correlation with clinical outcomes. This approach is valuable for monitoring patients before and after allogeneic stem cell transplantation.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Activating Flt3 mutations occur in approximately 30% of acute myeloid leukaemia (AML) cases.
- Flt3 mutations serve as specific targets for minimal residual disease (MRD) monitoring.
Purpose of the Study:
- To investigate the utility of Flt3 mutation-based MRD status in AML patients undergoing allogeneic peripheral blood stem cell transplantation (PBSCT).
- To assess the correlation between MRD status and clinical events in these patients.
Main Methods:
- Retrospective analysis of MRD status in four AML patients with diverse Flt3 mutations (juxtamembrane domain and tyrosine kinase domain).
- Utilized real-time polymerase chain reaction (PCR) for quantifying residual leukaemia cells at various time points post-PBSCT.
Main Results:
- Demonstrated a significant correlation between the dynamics of Flt3-based MRD status and clinical events across all four patients.
- The study highlights the clinical relevance of tracking MRD in AML patients with Flt3 mutations.
Conclusions:
- Flt3-based MRD status is a valuable tool for monitoring AML patients.
- This monitoring is impactful both prior to and following allogeneic PBSCT, aiding in treatment decisions and prognosis.